Equifax SEC filings document the company’s operating results, capital structure, governance, and material corporate agreements. Recent Form 8-K reports include quarterly financial-results releases and amendments to the company’s unsecured revolving credit facility involving Equifax and subsidiary borrowers.
Regulatory records also identify Equifax common stock listed on the New York Stock Exchange under EFX. Proxy materials cover annual meeting matters, board and shareholder voting topics, executive compensation, and company discussion of data, cloud technology, security, and EFX.AI within its public-company governance framework.
Form 144 notice by an Equifax insider to sell common stock. The filer intends to sell 4,553 shares of Equifax common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value reported as $1,111,895.40 and total shares outstanding listed as 123,797,380. The securities to be sold derive from stock options granted on 11/01/2019 (722 shares) and 09/28/2018 (3,831 shares); payment is shown as cash and the approximate date of sale is 08/29/2025. The filing indicates no securities were sold by the reporting person in the past three months and includes the standard representation that the seller knows of no undisclosed material adverse information about the issuer.
Form 144 notice for Equifax, Inc. (EFX) reporting a proposed sale of 3,764 common shares with an aggregate market value of $964,649.84 to be sold on 08/22/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing lists acquisition details for these shares as an option granted on 02/09/2024 with an acquisition date recorded as 08/22/2025 and payment in cash. An additional 1 share was acquired via dividend reinvestment on 06/12/2025. The filing also discloses a sale by Todd M. Horvath of 8,797 common shares on 08/20/2025 yielding $2,199,425.94. The notice includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.
Equifax insider sale by EVP/CFO/COO. John W. Gamble Jr., Equifax (EFX) executive, sold 3,000 shares of Common Stock on 08/18/2025 at $247.35 per share under a pre-established Rule 10b5-1 trading plan adopted 05/14/2025. After the sale he beneficially owns 62,202 shares, which figure includes accrued dividend equivalent units reinvested into restricted stock units through the company’s last dividend payment date. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/20/2025.
Equifax, Incorporated (EFX) filing a Form 144 notifies a proposed sale of 8,797 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $2,199,425.95. The filing shows the shares to be sold on 08/20/2025. The shares were acquired by option with grant date 05/01/2023 and the acquisition/expected sale date listed as 08/20/2025, with payment in cash. Total shares outstanding reported are 123,797,380. The filer certifies no undisclosed material adverse information and provides standard Rule 144 representations.
Equifax (EFX) Form 144 notice reports a proposed sale of 3,000 common shares through Fidelity Brokerage Services with an aggregate market value of $742,050. The shares represent restricted stock that vested and were acquired on 02/23/2024 as compensation from the issuer. The filing shows 123,797,380 shares outstanding and lists an approximate sale date of 08/18/2025 on the NYSE. The filer states there were no securities sold in the past three months and makes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
Equifax Inc. (EFX) Form 144 filing: CEO Mark W. Begor has filed notice to sell up to 48,264 common shares through Fidelity Brokerage on or after 07/28/2025. At the last reported market price, the proposed sale is valued at $11.85 million. The filing lists 123,797,380 shares outstanding, so the planned disposition equals roughly 0.04 % of total shares.
The shares come from two prior equity awards:
- 20,304 shares vested as restricted stock on 05/04/2021 (non-cash compensation).
- 27,960 shares from options granted 02/21/2020 and exercised for cash on 07/28/2025.
No additional financial metrics, earnings data, or company guidance are included in this short-form notice; the document solely satisfies SEC requirements for advance disclosure of certain insider sales.